IL162616A0 - Tetrahydroquinoline analogues as muscarinic agonists - Google Patents

Tetrahydroquinoline analogues as muscarinic agonists

Info

Publication number: IL162616A0
Authority: IL; Israel
Prior art keywords: compounds; muscarinic agonists; tetrahydroquinoline; methods; muscarinic receptor
Prior art date: 2001-12-28

Application number

IL16261602A

Other languages

English (en)

Original Assignee

Acadia Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-28

Filing date

2002-12-23

Publication date

2005-11-20

2002-12-23 Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc

2005-11-20 Publication of IL162616A0 publication Critical patent/IL162616A0/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

IL16261602A 2001-12-28 2002-12-23 Tetrahydroquinoline analogues as muscarinic agonists IL162616A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34472201P	2001-12-28	2001-12-28
PCT/US2002/041617 WO2003057672A2 (en)	2001-12-28	2002-12-23	Tetrahydroquinoline analogues as muscarinic agonists

Publications (1)

Publication Number	Publication Date
IL162616A0 true IL162616A0 (en)	2005-11-20

Family

ID=23351729

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL16261602A IL162616A0 (en)	2001-12-28	2002-12-23	Tetrahydroquinoline analogues as muscarinic agonists
IL162616A IL162616A (en)	2001-12-28	2004-06-17	Benzooxazine, benzothiazine and quinoline analogues as cholinergic receptor agonists and use thereof in the preparation of medicaments for treating diseases

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL162616A IL162616A (en)	2001-12-28	2004-06-17	Benzooxazine, benzothiazine and quinoline analogues as cholinergic receptor agonists and use thereof in the preparation of medicaments for treating diseases

Country Status (20)

Country	Link
US (3)	US7307075B2 (xx)
EP (1)	EP1461318B9 (xx)
JP (1)	JP4509565B2 (xx)
KR (1)	KR100972614B1 (xx)
CN (1)	CN100402032C (xx)
AT (1)	ATE304533T1 (xx)
AU (1)	AU2002359875B2 (xx)
BR (1)	BR0215430A (xx)
CA (1)	CA2470578C (xx)
DE (1)	DE60206198T2 (xx)
DK (1)	DK1461318T3 (xx)
ES (1)	ES2251624T3 (xx)
HK (1)	HK1074573A1 (xx)
IL (2)	IL162616A0 (xx)
MX (1)	MXPA04006281A (xx)
NO (1)	NO327522B1 (xx)
NZ (1)	NZ533566A (xx)
RU (1)	RU2292346C2 (xx)
WO (1)	WO2003057672A2 (xx)
ZA (1)	ZA200405024B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR0215430A (pt)	2001-12-28	2004-12-14	Acadia Pharm Inc	Composto e seus usos, composição, método de tratamento, método de aumento d atividade de um receptor colinérgico, método de tratamento e prevenção ou redução dos sintomas associados à disfunção em mamìferos
US7550459B2 (en) *	2001-12-28	2009-06-23	Acadia Pharmaceuticals, Inc.	Tetrahydroquinoline analogues as muscarinic agonists
EP1613321A2 (en) *	2003-03-28	2006-01-11	Acadia Pharmaceuticals Inc.	Muscarinic m1 receptor agonists for pain management
EP1900732A4 (en)	2005-06-24	2009-11-18	Toyama Chemical Co Ltd	NOVEL HETEROCYCLIC NITROGENIC COMPOUND AND SALT THEREOF
EP2258358A3 (en)	2005-08-26	2011-09-07	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en)	2005-08-26	2011-08-17	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
JP2009512711A (ja)	2005-10-21	2009-03-26	ブレインセルス，インコーポレイティド	Ｐｄｅ阻害による神経新生の調節
CA2625210A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
GB0607949D0 (en) *	2006-04-21	2006-05-31	Minster Res The Ltd	Mono and combination therapy
GB0607952D0 (en) *	2006-04-21	2006-05-31	Minster Res Ltd	Novel treatment
WO2007134136A2 (en)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenesis by modulating angiotensin
AU2007249435A1 (en)	2006-05-09	2007-11-22	Braincells, Inc.	5 HT receptor mediated neurogenesis
CN101522197B (zh) *	2006-07-31	2013-12-11	詹森药业有限公司	尾加压素ⅱ受体拮抗剂
KR20090064418A (ko)	2006-09-08	2009-06-18	브레인셀즈 인코퍼레이션	4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
ES2379762T3 (es)	2008-08-02	2012-05-03	Janssen Pharmaceutica N.V.	Antagonistas del receptor de la urotensina II
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
SG11201402405QA (en)	2011-11-18	2014-09-26	Heptares Therapeutics Ltd	Muscarinic m1 receptor agonists
GB201617454D0 (en)	2016-10-14	2016-11-30	Heptares Therapeutics Limited	Pharmaceutical compounds
GB201810239D0 (en)	2018-06-22	2018-08-08	Heptares Therapeutics Ltd	Pharmaceutical compounds
GB201819961D0 (en)	2018-12-07	2019-01-23	Heptares Therapeutics Ltd	Pharmaceutical compounds
GB201819960D0 (en)	2018-12-07	2019-01-23	Heptares Therapeutics Ltd	Pharmaceutical compounds
GB202020191D0 (en)	2020-12-18	2021-02-03	Heptares Therapeutics Ltd	Pharmaceutical compounds
WO2023114224A1 (en)	2021-12-13	2023-06-22	Sage Therapeutics, Inc.	Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3365457A (en)	1964-05-08	1968-01-23	Sterling Drug Inc	N [(1-, 2-, 3-indolyl)-lower alkyl]-1, 5-iminocycloalkane and-1, 5-iminocycloalkene derivatives
US3324137A (en)	1964-05-08	1967-06-06	Sterling Drug Inc	N-[indolyl-lower-alkanoyl]-1, 5-iminocycloalkanes and -iminocycloalkenes
JPS63290821A (ja) *	1987-05-25	1988-11-28	Otsuka Pharmaceut Co Ltd	抗不整脈剤
JP2886570B2 (ja) *	1989-09-29	1999-04-26	エーザイ株式会社	縮合ヘテロ環を有する化合物
US5149815A (en)	1991-04-29	1992-09-22	American Home Products Corporation	N-substituted-2-aminoquinolines
US5378698A (en)	1991-10-21	1995-01-03	Shionogi & Co., Ltd.	Benzothiazepine derivatives
US5457099A (en)	1992-07-02	1995-10-10	Sawai Pharmaceutical Co., Ltd.	Carbostyril derivatives and antiallergic agent
DE4228095A1 (de)	1992-08-24	1994-03-03	Asta Medica Ag	Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung
US5707798A (en) *	1993-07-13	1998-01-13	Novo Nordisk A/S	Identification of ligands by selective amplification of cells transfected with receptors
TW448161B (en) *	1994-07-14	2001-08-01	Otsuka Pharma Co Ltd	Cyclic amide derivatives
EA000875B1 (ru) *	1995-09-29	2000-06-26	ГЛАКСО ВЕЛЛКАМ С.п.А.	Тетрагидрохинолины в качестве антагонистов nmda (n-метил-d-аспарагиновой кислоты)
GB9617305D0 (en) *	1996-08-17	1996-09-25	Glaxo Wellcome Spa	Heterocyclic compounds
EP0934932A4 (en)	1996-08-22	2002-06-26	Meiji Seika Kaisha	CHINOLINE DERIVATIVES AND PSYCHOTROPES MEDIUM
US5919750A (en) *	1997-07-24	1999-07-06	Akzo Nobel Nv	Fabric softener composition
AU762726B2 (en) *	1998-03-31	2003-07-03	Acadia Pharmaceuticals, Inc.	Compounds with activity on muscarinic receptors
PL343317A1 (en) *	1998-03-31	2001-08-13	Warner Lambert Co	Benzoxazinones/benzothiazinones as serine protease inhibitors
CA2387535A1 (en)	1999-10-13	2001-04-19	Banyu Pharmaceutical Co., Ltd.	Substituted imidazolidinone derivatives
PT1464641E (pt) *	1999-12-30	2008-07-01	Lundbeck & Co As H	Derivados de 4-fenil-1-piperazinilo, -piperidinilo e -tetrahidropiridilo como antagonistas da dopamina d4
DE60129210T2 (de)	2000-02-29	2008-03-20	Mitsubishi Pharma Corp.	Zyklische amid-derivate
JP4119126B2 (ja)	2000-04-28	2008-07-16	アカディアファーマシューティカルズ，インコーポレーテッド	ムスカリン性アゴニスト
US6951849B2 (en)	2001-10-02	2005-10-04	Acadia Pharmaceuticals Inc.	Benzimidazolidinone derivatives as muscarinic agents
BR0215430A (pt)	2001-12-28	2004-12-14	Acadia Pharm Inc	Composto e seus usos, composição, método de tratamento, método de aumento d atividade de um receptor colinérgico, método de tratamento e prevenção ou redução dos sintomas associados à disfunção em mamìferos
EP1613321A2 (en)	2003-03-28	2006-01-11	Acadia Pharmaceuticals Inc.	Muscarinic m1 receptor agonists for pain management

2002
- 2002-12-23 BR BR0215430-7A patent/BR0215430A/pt not_active Application Discontinuation
- 2002-12-23 DE DE60206198T patent/DE60206198T2/de not_active Expired - Lifetime
- 2002-12-23 CA CA2470578A patent/CA2470578C/en not_active Expired - Fee Related
- 2002-12-23 WO PCT/US2002/041617 patent/WO2003057672A2/en active IP Right Grant
- 2002-12-23 ES ES02794441T patent/ES2251624T3/es not_active Expired - Lifetime
- 2002-12-23 EP EP02794441A patent/EP1461318B9/en not_active Expired - Lifetime
- 2002-12-23 JP JP2003557989A patent/JP4509565B2/ja not_active Expired - Fee Related
- 2002-12-23 AU AU2002359875A patent/AU2002359875B2/en not_active Ceased
- 2002-12-23 IL IL16261602A patent/IL162616A0/xx unknown
- 2002-12-23 DK DK02794441T patent/DK1461318T3/da active
- 2002-12-23 NZ NZ533566A patent/NZ533566A/en not_active IP Right Cessation
- 2002-12-23 AT AT02794441T patent/ATE304533T1/de active
- 2002-12-23 US US10/329,455 patent/US7307075B2/en not_active Expired - Fee Related
- 2002-12-23 MX MXPA04006281A patent/MXPA04006281A/es active IP Right Grant
- 2002-12-23 KR KR1020047010190A patent/KR100972614B1/ko not_active IP Right Cessation
- 2002-12-23 RU RU2004123203/04A patent/RU2292346C2/ru not_active IP Right Cessation
- 2002-12-23 CN CNB028270495A patent/CN100402032C/zh not_active Expired - Fee Related
2004
- 2004-06-17 IL IL162616A patent/IL162616A/en not_active IP Right Cessation
- 2004-06-24 ZA ZA2004/05024A patent/ZA200405024B/en unknown
- 2004-07-15 NO NO20043013A patent/NO327522B1/no not_active IP Right Cessation
2005
- 2005-08-08 HK HK05106785.1A patent/HK1074573A1/xx not_active IP Right Cessation
2006
- 2006-05-03 US US11/417,867 patent/US7576100B2/en not_active Expired - Fee Related
- 2006-05-03 US US11/417,865 patent/US7576078B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1461318A2 (en)	2004-09-29
US7576078B2 (en)	2009-08-18
WO2003057672A3 (en)	2003-11-13
EP1461318B1 (en)	2005-09-14
CA2470578A1 (en)	2003-07-17
WO2003057672A2 (en)	2003-07-17
CN100402032C (zh)	2008-07-16
CN1635891A (zh)	2005-07-06
DK1461318T3 (da)	2006-01-09
ATE304533T1 (de)	2005-09-15
NZ533566A (en)	2007-03-30
IL162616A (en)	2011-06-30
CA2470578C (en)	2010-10-12
AU2002359875B2 (en)	2009-01-08
RU2292346C2 (ru)	2007-01-27
KR100972614B1 (ko)	2010-07-27
DE60206198D1 (de)	2005-10-20
JP2005519060A (ja)	2005-06-30
JP4509565B2 (ja)	2010-07-21
US20060199813A1 (en)	2006-09-07
AU2002359875A1 (en)	2003-07-24
DE60206198T2 (de)	2006-06-14
NO327522B1 (no)	2009-08-03
KR20040070287A (ko)	2004-08-06
US7576100B2 (en)	2009-08-18
US20030176418A1 (en)	2003-09-18
RU2004123203A (ru)	2006-01-20
NO20043013L (no)	2004-07-28
US20060199810A1 (en)	2006-09-07
HK1074573A1 (en)	2005-11-18
ZA200405024B (en)	2005-07-27
BR0215430A (pt)	2004-12-14
EP1461318B9 (en)	2005-12-28
ES2251624T3 (es)	2006-05-01
MXPA04006281A (es)	2004-09-27
US7307075B2 (en)	2007-12-11

Publication	Publication Date	Title
HK1074573A1 (en)	2005-11-18	Tetrahydroquinoline analogues as muscarinic agonists
TW200634006A (en)	2006-10-01	Tetrahydroquinoline analogues as muscarinic agonists
MXPA04006280A (es)	2004-09-27	Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
NO20022655L (no)	2002-06-05	<Beta>-2-adrenerge reseptoragonister
AP1498A (en)	2005-11-21	Inhibitors of impdh enzyme.
WO2004052348A3 (en)	2004-10-21	Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
NO20013443D0 (no)	2001-07-11	Triazolforbindelser med dopamin-D3-reseptoraktivitet
IL142768A0 (en)	2002-03-10	N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
MXPA02012712A (es)	2003-04-25	N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
IL195256A0 (en)	2009-08-03	Compositions of r(+)and s(-)pramipexole and methods of using the same
IL175762A0 (en)	2008-04-13	Use of substituted 2-aminotetralines for the preventative treatment of parkinson's disease
NO20035025L (no)	2003-11-12	Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
ATE293691T1 (de)	2005-05-15	Myostatin genpromoter und inhibierung dessen aktivierung
EP1178988A4 (en)	2004-10-06	THERAPEUTIC COMPOUNDS AND METHODS
GB0322510D0 (en)	2003-10-29	Novel compounds
EP1254260A4 (en)	2003-07-23	METHODS FOR DIAGNOSING AND TREATING A HEART DISEASE
MXPA03008801A (es)	2004-02-18	Aril oxima-piperazinas utiles como antagonistas de ccr5.
WO2003105891A3 (en)	2004-05-06	USE OF HEC1 ANTAGONISTS IN THE TREATMENT OF PROLIFERATIVE DISORDERS AND CANCERS
EP1260221A3 (en)	2002-12-18	Combination treatment for depression and anxiety
WO2003092475A3 (en)	2004-10-07	Diagnosis and treatment of glaucoma
RU2001101227A (ru)	2002-11-10	Антибактериальное средство для лечения кожных заболеваний